Ruth Plummer
Newcastle upon Tyne Hospitals NHS Foundation Trust · 726 works · 14,299 citations · h-index 60
Top works
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
- Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma
- Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
- Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
- Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
- Clinical development of new drug–radiotherapy combinations
- The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- 622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors
- ALIMTATM in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial